BACKGROUND: A booster meningococcal C (MenC) vaccine dose is recommended after the first year of life. The objective of this study was to assess its immunogenicity and factors that modify the immunoresponse. METHODS: An open label study in which 389 children 14 to 18 months of age, previously primed with 3 doses of aMenC vaccine conjugated with CRM197 (MenC-CRM) or with 2 doses of a MenC vaccine conjugated with tetanus toxoid (MenC-TT), were randomized to be boosted with either of these vaccines and a DTaP-IPV-Hib vaccine at the same time. Immunogenicity against MenC and Haemophilus influenzae type b was assessed before and 1 month after the booster dose. RESULTS: Before the second year booster, 44.9% of the studied children had MenC bactericidal (SBA) seroprotection rate of > or =1:8, with no differences related to the vaccine used for priming, whereas the anti Hib antibody concentration was higher in children primed with the MenC-TT (0.59; 95% CI: 0.49-0.71 vs. 0.39; 95% CI: 0.32-0.48).One month after the MenC vaccine booster 99.5% of the children had SBA > or =1:128. Children primed with MenC-TT reached higher SBA titers: 6520 (95% CI: 5359-7932) than those primed with MenC-CRM: 1903 (95% CI: 1600-2262). Children primed with MenC-CRM had SBA titers of 2061 (95% CI: 1599-2627) when boosted with MenC-TT and 1746 (95% CI: 1378-2213) when boosted with MenC-CRM. Children primed with MenC-TT had SBA titers of 6786 (95% CI: 5023-9167) and 6278 (95% CI: 4841-8144) when boosted with MenC-TT or MenC-CRM. There was no difference in the PRP antibody concentration after boosting. CONCLUSIONS: A booster MenC dose induces high SBA and anti Hib response with over 99% of children seroprotected. Children primed with a MenC-TT vaccine reached SBA titers 3.5 times higher no matter which vaccine was used for boosting.
RCT Entities:
BACKGROUND: A booster meningococcal C (MenC) vaccine dose is recommended after the first year of life. The objective of this study was to assess its immunogenicity and factors that modify the immunoresponse. METHODS: An open label study in which 389 children 14 to 18 months of age, previously primed with 3 doses of a MenC vaccine conjugated with CRM197 (MenC-CRM) or with 2 doses of a MenC vaccine conjugated with tetanus toxoid (MenC-TT), were randomized to be boosted with either of these vaccines and a DTaP-IPV-Hib vaccine at the same time. Immunogenicity against MenC and Haemophilus influenzae type b was assessed before and 1 month after the booster dose. RESULTS: Before the second year booster, 44.9% of the studied children had MenC bactericidal (SBA) seroprotection rate of > or =1:8, with no differences related to the vaccine used for priming, whereas the anti Hib antibody concentration was higher in children primed with the MenC-TT (0.59; 95% CI: 0.49-0.71 vs. 0.39; 95% CI: 0.32-0.48).One month after the MenC vaccine booster 99.5% of the children had SBA > or =1:128. Children primed with MenC-TT reached higher SBA titers: 6520 (95% CI: 5359-7932) than those primed with MenC-CRM: 1903 (95% CI: 1600-2262). Children primed with MenC-CRM had SBA titers of 2061 (95% CI: 1599-2627) when boosted with MenC-TT and 1746 (95% CI: 1378-2213) when boosted with MenC-CRM. Children primed with MenC-TT had SBA titers of 6786 (95% CI: 5023-9167) and 6278 (95% CI: 4841-8144) when boosted with MenC-TT or MenC-CRM. There was no difference in the PRP antibody concentration after boosting. CONCLUSIONS: A booster MenC dose induces high SBA and anti Hib response with over 99% of children seroprotected. Children primed with a MenC-TT vaccine reached SBA titers 3.5 times higher no matter which vaccine was used for boosting.
Authors: Elizabeth Miller; Nick Andrews; Pauline Waight; Helen Findlow; Lindsey Ashton; Anna England; Elaine Stanford; Mary Matheson; Joanna Southern; Elizabeth Sheasby; David Goldblatt; Ray Borrow Journal: Clin Vaccine Immunol Date: 2010-12-29
Authors: Richarda M de Voer; Liesbeth Mollema; Rutger M Schepp; Sabine C de Greeff; Pieter G M van Gageldonk; Hester E de Melker; Elisabeth A M Sanders; Guy A M Berbers; Fiona R M van der Klis Journal: PLoS One Date: 2010-08-13 Impact factor: 3.240
Authors: Enrique Chacon-Cruz; David E Sugerman; Michele M Ginsberg; Jackie Hopkins; Jose Antonio Hurtado-Montalvo; Jose Luis Lopez-Viera; Cesar Arturo Lara-Muñoz; Rosa M Rivas-Landeros; Maria Luisa Volker; John A Leake Journal: Emerg Infect Dis Date: 2011-03 Impact factor: 6.883
Authors: Ameneh Khatami; Elizabeth A Clutterbuck; Amber J Thompson; Jennifer A McKenna; David Pace; Jacqueline Birks; Matthew D Snape; Andrew J Pollard Journal: PLoS One Date: 2014-07-14 Impact factor: 3.240
Authors: Fatima Mir; Farheen Quadri; Ondrej Mach; Imran Ahmed; Zaid Bhatti; Asia Khan; Najeeb Ur Rehman; Elias Durry; Maha Salama; Steven M Oberste; William C Weldon; Roland W Sutter; Anita K M Zaidi Journal: Lancet Infect Dis Date: 2015-06-17 Impact factor: 25.071
Authors: Timo Vesikari; Aino Forstén; Dominique Boutriau; Véronique Bianco; Marie Van der Wielen; Jacqueline M Miller Journal: Hum Vaccin Immunother Date: 2012-10-02 Impact factor: 3.452
Authors: Susanne P Stoof; Fiona R M van der Klis; Debbie M van Rooijen; Mirjam J Knol; Elisabeth A M Sanders; Guy A M Berbers Journal: PLoS One Date: 2014-06-25 Impact factor: 3.240